Optimer Pharmaceuticals

PharmaEssentia Appoints Robert Geller, M.D. as Head of Medical and Shawn Gibbs, J.D. as Head of Legal

Retrieved on: 
Wednesday, April 24, 2024
Research, Legal, Clinical Trials, Professional Services, Other Health, Biotechnology, Pharmaceutical, Health, Science, Oncology, Shawn, Massachusetts Institute of Technology, University, Vion Pharmaceuticals, Optimer Pharmaceuticals, Physics, Pancreatic serous cystadenoma, Safety, Pharmacovigilance, Hematology, GE HealthCare, Grinnell College, Partnership, Alexion Pharmaceuticals, Partner, Senior, Corporate lawyer, Patient, Medicine, Multimedia, Marketing, Drug development, Harvard Medical School, Associate, Trade, Ophthalmology, Ovarian cancer, Gerber Products Company, Platinum, Strategic planning, Pharmaceutical industry

View the full release here: https://www.businesswire.com/news/home/20240423922725/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240423922725/en/
    Dr. Robert Geller is a medical oncologist with diverse expertise across the biotechnology industry and in academia, including in drug development, medical affairs, business development and as a clinical scientist.
  • As the new Head of Medical at PharmaEssentia, Dr. Geller will be responsible for U.S. clinical operations, reporting to Chief Medical Officer, Albert Qin, M.D., Ph.D.
  • joins PharmaEssentia with extensive experience across legal affairs in the biopharmaceutical industry, including in corporate transactions, governance, compliance, litigation, regulatory matters, and strategic planning.
  • Prior, he held several legal positions with Sequirus, Inc., including most recently Executive Director, Associate General Counsel, Americas, within Commercial Development and Medical Affairs.

Imvax Provides Corporate Update

Retrieved on: 
Wednesday, September 6, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Spark Therapeutics, University, GBM, Wharton School of the University of Pennsylvania, Roche, Optimer ligand, Dartmouth College, Cubist Pharmaceuticals, Immunotherapy, Economics, Acquisition, Patient, Diagnosis, SVP, Therapy, Optimer Pharmaceuticals, Pharmaceutical industry, Management

The trial is enrolling as expected, and the company will continue additional fundraising over the next several months.

Key Points: 
  • The trial is enrolling as expected, and the company will continue additional fundraising over the next several months.
  • The company also announced the appointment of Stephen Webster to the Imvax Board of Directors.
  • “I am excited to join the Imvax Board of Directors at a time of tremendous opportunity for the company,” said Mr. Webster.
  • I look forward to working with the Imvax management team and Board to help realize the company’s mission to deliver transformative therapies for patients.”

Immix Biopharma Subsidiary Nexcella Appoints Henry McKinnell, Jr., former Chairman & CEO of Pfizer Inc., to Board of Directors

Retrieved on: 
Monday, June 12, 2023
Amgen, University, Pfizer, Multiple myeloma, Senior advisor, McKinnell, Business, Pharmaceutical Research and Manufacturers of America, Pharmacy, Merck & Co., Cubist Pharmaceuticals, Retirement, Stanford Graduate School of Business, Amyloidosis, ExxonMobil, Toyota Motor Corporation Tahara plant, Merck, LOS, Optimer Pharmaceuticals, Management, Pharmaceutical industry, Cubism, Agility Logistics

LOS ANGELES, June 12, 2023 (GLOBE NEWSWIRE) -- Nexcella, Inc., a subsidiary of Immix Biopharma, Inc. (“Nexcella”, “Company”, “We” or “Us”), today announced that effective today, Henry A. McKinnell, Jr, Ph.D., former Chairman and Chief Executive Officer of Pfizer Inc., has been appointed to the Company’s Board of Directors. Dr. McKinnell brings significant leadership to Nexcella: developing, launching and commercializing drug candidates; building world-class operations; and forming international alliances.

Key Points: 
  • Dr. McKinnell brings significant leadership to Nexcella: developing, launching and commercializing drug candidates; building world-class operations; and forming international alliances.
  • After joining Pfizer, Inc. in 1971, Dr. McKinnell held positions of increasing responsibility around the world including Chairman and Chief Executive Officer from 2001 until his retirement in 2006.
  • Most recently, Dr. McKinnell was the independent Chairman of Moody’s Corporation from 2012 to 2021.
  • “We are honored to have Dr. McKinnell join the Nexcella Board of Directors.

Nexcella Appoints Henry McKinnell, Jr., former Chairman & CEO of Pfizer Inc., to Board of Directors

Retrieved on: 
Monday, June 12, 2023
Amgen, University, Pfizer, Multiple myeloma, Senior advisor, McKinnell, Business, Pharmaceutical Research and Manufacturers of America, Pharmacy, Merck & Co., Cubist Pharmaceuticals, Retirement, Stanford Graduate School of Business, Amyloidosis, ExxonMobil, Toyota Motor Corporation Tahara plant, Merck, LOS, Optimer Pharmaceuticals, Management, Pharmaceutical industry, Cubism, Agility Logistics

Dr. McKinnell brings significant leadership to Nexcella: developing, launching and commercializing drug candidates; building world-class operations; and forming international alliances.

Key Points: 
  • Dr. McKinnell brings significant leadership to Nexcella: developing, launching and commercializing drug candidates; building world-class operations; and forming international alliances.
  • After joining Pfizer, Inc. in 1971, Dr. McKinnell held positions of increasing responsibility around the world including Chairman and Chief Executive Officer from 2001 until his retirement in 2006.
  • Most recently, Dr. McKinnell was the independent Chairman of Moody’s Corporation from 2012 to 2021.
  • “We are honored to have Dr. McKinnell join the Nexcella Board of Directors.

Vesigen Therapeutics Appoints Paulash Mohsen as Chief Executive Officer

Retrieved on: 
Monday, April 11, 2022
Science, Other Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Infectious Diseases, Therapy, Amyotrophic lateral sclerosis, Cell, Merck & Co., Virus, Cubist Pharmaceuticals, Cytoplasm, Horizontal Environmental Genetic Alteration Agents, Chemical engineering, Intrinsic termination, ARMM Regional Legislative Assembly, Board, RNA, Brown University, Biotechnology, Doctor of Philosophy, Yuman–Cochimí languages, Harvard University, Harvard T.H. Chan School of Public Health, Tissue, Public health, Exosome, Seminal vesicles, Technology, Pfizer, Massachusetts Institute of Technology, Protein, Cubism, Physiology, Business operations, RNA transfection, MBA, Harvard Business School, HIV, Enzyme, Genetics, Optimer Pharmaceuticals, Acquisition, Patient, Pharmaceutical industry, Vaccine, Merck

Vesigen Therapeutics, Inc., a biotechnology company pioneering a novel extracellular vesicle delivery technology, ARMMs, today announced the appointment of Paulash Mohsen as Chief Executive Officer.

Key Points: 
  • Vesigen Therapeutics, Inc., a biotechnology company pioneering a novel extracellular vesicle delivery technology, ARMMs, today announced the appointment of Paulash Mohsen as Chief Executive Officer.
  • On behalf of our Board and management team, we welcome Paulash and look forward to his executive leadership.
  • Mr. Mohsen is a seasoned biopharmaceutical executive who has served in a variety of roles across multiple disciplines.
  • Prior to his appointment at Vesigen, he served as Chief Business Officer at Yumanity Therapeutics, and helped the company grow from a seed stage, research-based startup to a public company, with a lead clinical program in Parkinsons disease.

Global Aptamers Market 2021 to 2026: Rising R&D Investments in Biotechnology and Pharmaceutical Industries - ResearchAndMarkets.com

Retrieved on: 
Wednesday, December 22, 2021
Biotechnology, Pharmaceutical, Genetics, Health, Aptamer, DNA, RNA, Technology, US, Overalls, Efficiency, Investment, Organic acid, Federalisation of the European Union, Growth, Protein, Diagnosis, Therapy, Development, Optimer Pharmaceuticals, European Federation of Pharmaceutical Industries and Associations, Biotechnology, Research and development, Industry, Carbohydrate, Office of the National Investment Council of Ukraine, Antibody, Acceleration, Partnership, Peptide, Fine chemical, Pharmaceutical industry, Research

The "Global Aptamers Market - Forecasts from 2021 to 2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Aptamers Market - Forecasts from 2021 to 2026" report has been added to ResearchAndMarkets.com's offering.
  • The global aptamers market is estimated to be valued at US$1,068.804 million in 2019 and is projected to grow rapidly during the forecast period.
  • The acceleration in the investments in Research and Development is expected to make a positive impact on the overall market growth.
  • The market is expected to surge in the coming years, due to the growth in R&D investments in the pharmaceutical and biotechnology industries.